Filana Therapeutics, Inc. last reported quarterly results on Nov 5, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026). It usually reports 29–71 days after a quarter ends. Based on that pattern, the next release is estimated for around Mar 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Thursday. Based on last year's release for the same quarter on Mar 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 29–71 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 5, 2026
36 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
—
|
-11
+0.7%
|
—
|
|
Jul 29, 2026
29 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
—
|
-9
+80.5%
|
—
|
|
May 7, 2026
37 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
—
|
-10
+55.9%
|
—
|
|
Mar 12, 2026
71 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
—
|
-13
+54.6%
|
-0.26
+54.8%
|
|
Nov 12, 2025
43 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
—
|
-11
+61.3%
|
-0.22
+62.1%
|
|
Aug 14, 2025
45 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
—
|
-44
-818.5%
|
-0.92
-807.7%
|
|
May 8, 2025
38 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
—
|
-23
-193.5%
|
-0.48
-11.6%
|
|
Jan 7, 2025
7 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
—
|
-28
-31.9%
|
-0.57
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- FLNA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Austin, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1069530
- Former names
- CASSAVA SCIENCES INC (until Feb 19, 2026); PAIN THERAPEUTICS INC (until Mar 25, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.